Page last updated: 2024-10-27

glimepiride and Glucose Intolerance

glimepiride has been researched along with Glucose Intolerance in 9 studies

glimepiride: structure given in first source

Glucose Intolerance: A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.

Research Excerpts

ExcerptRelevanceReference
"Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)."9.17Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus."9.17Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."9.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a biomarker and mediator of cardiovascular disease in patients with impaired glucose tolerance (IGT) or diabetes mellitus (DM)."5.17Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. ( Imaizumi, T; Mizoguchi, M; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"Our study indicated that pioglitazone decreased the visceral fat volume and its metabolic activity in patients with impaired glucose tolerance or type 2 diabetes mellitus."5.17Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. ( Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S, 2013)
"The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging."5.15Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011)
"With single doses, there was a clear dose-response relationship for the reduction in AUC, with a statistically significant difference only between placebo (mean 1981, 95% confidence intervals (CI) 1883-2078) and 2 mg glimepiride (mean 1763, 95% CI 1665-1861)."2.70The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. ( Lindblad, U; Lindwall, K; Melander, A; Ranstam, J; Sjöstrand, A, 2001)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Niedowicz, DM1
Özcan, S1
Nelson, PT1
Tahara, N3
Yamagishi, S3
Mizoguchi, M3
Tahara, A3
Imaizumi, T3
Kodama, N2
Honda, A1
Nitta, Y2
Kaida, H2
Ishibashi, M2
Abe, T1
Ikeda, H2
Narula, J2
Fukumoto, Y1
Ramanathan, RP1
Arbeláez, AM1
Cryer, PE1
Tawakol, A1
Finn, AV1
Oba, T1
Mawatari, K1
Yasukawa, H1
Hayabuchi, N1
Harada, H1
Marwick, TH1
Kawamori, R1
Lindblad, U1
Lindwall, K1
Sjöstrand, A1
Ranstam, J1
Melander, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study[NCT02999841]Phase 4100 participants (Anticipated)Interventional2016-03-31Recruiting
Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631]70 participants (Actual)Interventional2007-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for glimepiride and Glucose Intolerance

ArticleYear
[Therapies for newly-onset diabetic patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2

    Topics: Acarbose; Cyclohexanes; Diabetes Mellitus, Type 2; Diet Therapy; Enzyme Inhibitors; Exercise Therapy

2005

Trials

5 trials available for glimepiride and Glucose Intolerance

ArticleYear
Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes.
    Rejuvenation research, 2013, Volume: 16, Issue:5

    Topics: Aged; Aged, 80 and over; Arginine; Diabetes Mellitus, Type 2; Female; Fibronectins; Glucose Intolera

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:11

    Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglu

2013
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.
    Diabetes, 2011, Volume: 60, Issue:4

    Topics: Adult; Blood Glucose; C-Peptide; Diazoxide; Female; Glucagon; Glucose Intolerance; Humans; Hypoglyce

2011
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive

2011
The NEPI antidiabetes study (NANSY). 1: short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose.
    Diabetes, obesity & metabolism, 2001, Volume: 3, Issue:6

    Topics: Blood Glucose; Body Constitution; Body Mass Index; Cholesterol; Dose-Response Relationship, Drug; Do

2001

Other Studies

3 other studies available for glimepiride and Glucose Intolerance

ArticleYear
Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice.
    Journal of diabetes research, 2018, Volume: 2018

    Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Female; Gluconeogenes

2018
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art

2011
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
    JACC. Cardiovascular imaging, 2011, Volume: 4, Issue:10

    Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus,

2011